Conexeu Sciences Inc. (NASDAQ: CNXU) announced the appointment of five new leadership team members following its recent Nasdaq listing. The biotechnology company expanded its board of directors from six to nine members and named a new chief commercial officer.

The company appointed Ana Bastiani-Posner, April Burke, and Andrew Costa to its board of directors. Bastiani-Posner serves as Executive Vice President and Chief Financial Officer of Kyowa Kirin North America, which oversees approximately $1.2 billion in annual revenue. Burke is Executive Vice President and Chief Financial Officer of Lucid Hearing. Costa is Co-Managing Partner of RX3 Growth Partners, a consumer-focused growth equity firm.

Conexeu named co-founder and director David Bogart as Chief Commercial Officer. Bogart has advised companies on more than $75 million in capital formation and brings experience in public market strategy and investor communications.

The company also added Melinda Farina to its advisory board. Farina founded Integrated Aesthetics Consulting Inc. and Beauty Brokers Inc., a global plastic surgery consultancy.

"Conexeu is entering an exciting new phase of growth, and it is important that our leadership team reflects the breadth of expertise needed to support both our scientific vision and business strategy," said Miles Harrison, CEO and President of Conexeu Sciences.

The appointments follow Conexeu's recent Nasdaq listing and bell-ringing ceremony. The company is developing regenerative tissue technologies, including the preclinical development of B.R.E.A.S.T., a 3D-bioprinted breast matrix for reconstruction applications. The company plans to submit a 510(k) application to the FDA in early 2027 for its initial indication.